Quarterly report pursuant to Section 13 or 15(d)

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative)

v3.10.0.1
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative) - USD ($)
3 Months Ended 6 Months Ended 12 Months Ended
Jun. 30, 2018
Jun. 30, 2017
Jun. 30, 2018
Jun. 30, 2017
Dec. 31, 2017
Cash $ 3,643,316   $ 3,643,316   $ 3,027,033
Depreciation expense 10,897 $ 1,187 $ 20,578 $ 1,213  
Useful Life of patents and other technologies     5 years    
Impairment loss     $ 0 0 (1,321,338)
Intangible assets acquired         1,583,260
Due to related parties 450,000   450,000   450,000
Deferred rental income 11,182   11,182   $ 12,769
Shipping and Handling Costs     25 0  
Research and Development     263 0  
Advertising and Marketing Costs     $ 0 0  
Reverse split ratio     1:4    
Beijing GenExosome | Dr. Yu Zhou          
Equity interests ownership percentage         40.00%
Real property operating [Member]          
Depreciation expense 31,806 $ 32,943 $ 63,611 32,943  
Shipping and Handling Costs     0 0  
Research and Development     263 0  
Advertising and Marketing Costs     0 $ 0  
PRC [Member]          
Cash 1,318,799   1,318,799   $ 1,327,009
United States [Member]          
Cash $ 2,324,517   $ 2,324,517   $ 1,700,024